Source: Indian Pharma Post

Edity: Dr. Reddy's Laboratories acquires Preferred A-1 shares of Edity Therapeutics

The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares

Read full article »
Est. Annual Revenue
$100K-5.0M
Est. Employees
1-25
Michal Golan-Mashiach's photo - Co-Founder & CEO of Edity

Co-Founder & CEO

Michal Golan-Mashiach

CEO Approval Rating

90/100

Read more